DBDenzil R. Beukes

Denzil R. Beukes

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Denzil R. Beukes has a total of 14 co-authors. Here are the top co-authors by number of shared publications:

  • Anthonia F. Afolayan

    Division of Pharmaceutical Chemistry, Faculty of Pharmacy, Rhodes University, Grahamstown, South Africa

    2 shared publications
  • John J. Bolton

    University of Cape Town

    2 shared publications
  • Peter J. Smith

    Division of Pharmacology, Department of Medicine, University of Cape Town, K-45 OMB, Groote Schuur Hospital, Observatory, South Africa

    2 shared publications
  • Adrienne Lesley Edkins

    The Biomedical Biotechnology Research Unit (BioBRU), Department of Biochemistry and Microbiology, Rhodes University, Makhanda, 6139, South Africa

    1 shared publication
  • Carmen A. Lategan

    Division of Pharmacology, University of Cape Town, Observatory, 7925, South Africa

    1 shared publication
  • Carmen Lategan

    Division of Pharmacology, Department of Medicine, University of Cape Town, K-45 OMB, Groote Schuur Hospital, Observatory, South Africa

    1 shared publication

Latest Publications

  • Open Access

    Assessment of potential anti-cancer stem cell activity of marine algal compounds using an in vitro mammosphere assay

    by Jo-Anne de la Mare, Jason N Sterrenberg, Mugdha G Sukhthankar, Maynard T Chiwakata, Denzil R Beukes, Gregory L Blatch, Adrienne L Edkins

    Background: The cancer stem cell (CSC) theory proposes that tumours arise from and are sustained by a subpopulation of cells with both cancer and stem cell properties. One of the key hallmarks of CSCs is the ability to grow anchorage-independently under serum-free culture conditions resulting in the formation of tumourspheres. It has further been reported that these cells are resistant to traditional chemotherapeutic agents. Methods: In this study, the tumoursphere assay was validated in MCF-7 cells and used to screen novel marine algal compounds for potential anti-cancer stem cell (CSC) activity in vitro. Results: MCF-7 breast cancer cells were observed to generate tumourspheres or mammospheres after 3-5 days growth in anchorage-independent conditions and an apparent enrichment in potential CSCs was observed by an increase in the proportion of CD44high/CD24low marker-bearing cells and Oct4 expression compared to those in the bulk population grown in regular adherent conditions. Using this assay, a set of algal metabolites was screened for the ability to inhibit mammosphere development as a measure of potential anti-CSC activity. We report that the polyhalogenated monoterpene stereoisomers RU017 and RU018 isolated from the red alga Plocamium cornutum, both of which displayed no cytotoxicity against either adherent MCF-7 breast cancer or MCF-12A non-transformed breast epithelial cells, were able to prevent MCF-7 mammosphere formation in vitro. On the other hand, neither the brown algal carotenoid fucoxanthin nor the chemotherapeutic paclitaxel, both of which were toxic to adherent MCF-7 and MCF-12A cells, were able to inhibit mammosphere formation. In fact, pre-treatment with paclitaxel appeared to enhance mammosphere formation and development, a finding which is consistent with the reported resistance of CSCs to traditional chemotherapeutic agents. Conclusion: Due to the proposed clinical significance of CSC in terms of tumour initiation and metastasis, the identification of agents able to inhibit this subpopulation has clinical significance.


  • Open Access

    Antiplasmodial and antimicrobial activities of South African marine algal extracts

    by Carmen Lategan, Tracy Kellerman, Anthonia F. Afolayan, Maryssa G. Mann, Edith M. Antunes, Peter J. Smith, John J. Bolton, Denzil R. Beukes

    Seventy-eight crude organic fractions from nineteen species of marine algae collected from the coast of South Africa were screened for activity against a chloroquine sensitive strain of Plasmodium falciparum (D10), Staphylococcus aureus, Klebsiella pneumoniae, Mycobacterium aurum and Candida albicans. Fifteen crude fractions showed good antiplasmodical activity (IC50 Sargassum heterophyllum (Turner) C. Agardh (Sargassaceae) was the most active with an IC50 value of 2.8 μg/mL. Eleven extracts showed MIC values ≤ 1 mg/mL against at least one of S. aureus, K. pneumoniae, M. aurum and C. albicans. The broadest spectrum of antimicrobial activity was exhibited by the aqueous-HP20 fraction of Polysiphonia incompta Harvey (Rhodomelaceae). This study shows that marine algae not only produce antimicrobial compounds but also may be a source of antimalarial lead compounds.


  • Open Access

    Fucoxanthin, Tetraprenylated Toluquinone and Toluhydroquinone Metabolites from Sargassum heterophyllum Inhibit the in vitro Growth of the Malaria Parasite Plasmodium falciparum

    by Anthonia F. Afolayan, John J. Bolton, Carmen A. Lategan, Peter J. Smith, Denzil R. Beukes

    In the course of our search for antimalarial leads from marine algae, four metabolites, sargaquinoic acid, sargahydroquinoic acid, sargaquinal and fucoxanthin, were isolated from the South African alga Sargassum heterophyllum. Fucoxanthin and sargaquinal showed good antiplasmodial activity toward a chloroquine-sensitive strain (D10) of Plasmodium falciparum (IC50 1.5 and 2.0 μm, respectively), while sargaquinoic acid and sargahydroquinoic acid were only moderately active (IC50 12.0 and 15.2 μm, respectively).